POSTER: ABCL-323 Hypoxia-Specific Imaging Before CAR-T Therapy in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
Divita Pandita(University of California, San Francisco), Charalambos Andreadis(University of California, San Francisco), Madhav Seshadri(University of California, San Francisco), Rahul Banerjee(University of Washington), Michelle T. Leonard(University of California, San Francisco), Michael Malek‐Ahmadi(Banner Sun Health Research Institute), Weiyun Z. Ai(City College of San Francisco), Chiung‐Yu Huang, Bita Fakhri(University of California, San Francisco), Victoria Wang(IIT@Harvard), Lawrence Kaplan(University of California, San Francisco), Michael A. Spinner(Stanford Medicine), Siobhan Larue(University of California, San Francisco), Miguel Hernandez Pampaloni(University of California, San Francisco)
Cited by 0
Related Papers
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
|Nature Genetics|2017|590
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523